Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URSa-1: Pembrolizumab in Ultra-Rare Sarcomas
NCT07089992Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT07089992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089992.